Current studies into retatrutide, a dual activator for GLP-1 and GIP receptors, are revealing promising outcomes in treating weight gain and type non-insulin-dependent disease. Initial data suggest a novel mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/